GenVec Inc, Gaithersburg, Md, presented data on its respiratory syncytial virus (RSV) vaccine program at the 8th Annual International Respiratory Syncytial Virus Symposium in Santa Fe, NM, last week.
According to the company, the data presented demonstrated the universal RSV vaccine candidate is “highly immunogenic and produces durable and broad protection from a single intramuscular administration.” Moreover, protection in cotton rat and mouse models was characterized by functional RSV neutralizing antibodies and no disease potentiation was observed.
GenVec’s RSV vaccine candidate uses a proprietary adenovirus that is capable of generating a broad immune response while avoiding the problems of vector specific immunity that has hampered other vectored vaccines, according to the company.
Source: GenVec Inc
